Professor Robert Hills
- The Early Breast Cancer Trialists' Collaborative Group (EBCTCG)
- A comparison of individual patient data (IPD) over meta-analyses of published data, implications for clinical trial design and the utility of endpoints for early breast cancer trials. CRUK STUDENTSHIP AVAILABLE
- Assessing benefits and harms in early breast cancer: predictive and prognostic factors in early breast cancer and long-term side-effects of therapy. CRUK STUDENTSHIP AVAILABLE
Professor of Medical Statistics
Robert Hills studied mathematics at the University of Oxford, where his DPhil was on exploration of symmetries with applications to superconductivity. He joined the CTSU in 1993 as a programmer on the QUASAR trial in colorectal cancer. Following a brief period working in low temperature physics at the University of Nottingham, he moved to the University of Birmingham Clinical Trials Unit (BCTU) in 1997.There, he worked on clinical trials in Acute Myeloid Leukaemia, Alzheimer’s Disease, women’s health and many others as well as large scale individual patient data meta-analyses of treatment for colorectal cancer.
In 2006, he moved to Cardiff University as statistical lead for the NCRI/MRC trials in Acute Myeloid Leukaemia. During his 12 years in Cardiff he was head of the Haematology Clinical Trials Unit, and latterly led on clinical cancer research methodology and haematological malignancies. The novel designs used in these trials allow the clinical value of disease monitoring to be evaluated, as well as numerous targeted therapies in designs that allow for an early change from an unpromising new therapy to one with greater potential. Additionally, he continued his work on the integration of laboratory and clinical data, and on individual patient data meta-analyses, where he demonstrated a survival benefit for gentuzumab ozogamicin in AML.
In 2018, he moved back to the University of Oxford where he is part of the Early Breast Cancer Trialists' Collaborative Group.
What drives CAR-T emergent cytopenia?
Hills RK., (2023), Br J Haematol
Anthracycline and taxane containing chemotherapy for early-stage operable breast cancer: meta-analyses of 100,000 women in 86 randomised trials
Taylor CAROLYN. et al, (2023), The Lancet
Early mortality risk with non-intensive acute myeloid leukemia (AML) therapies: analysis of 1336 patients from MRC/NCRI and SWOG.
Othus M. et al, (2022), Leuk Lymphoma, 1 - 3
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Love SB. et al, (2022), Trials, 23
Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type Diffuse Large B Cell Lymphoma.
Bewicke-Copley F. et al, (2022), Blood Adv